Competition Regulation and Recombinant Drugs in India
Requires Subscription or Fee PDF


recombinant drugs
SCP model


The recombinant drug industry is growing at almost 20% rate in India. The long term growth of this sector depends upon the innovation as well as competition and market. The structure, conduct and performance of firms in market plays a very important role in predicting the future of innovation and competition in market. The present paper analyses the structure-conduct-performance paradigm in the context of recombinant drug sector in India. The analysis reveals that R&D, distribution chains and advertisement has significant effect on the profits of firms in the recombinant drug sector.
Requires Subscription or Fee PDF


Bhupinder Singh Sekhon, Biopharmaceuticals: an overview, Thai J. Pharm. Sci. 34 (2010) 1-19; Massimo Riccaboni, Biopharmaceuticals Availability, Diffusion, Sustainability available at

Association of Biotechnology Led Enterprises (ABLE), PriceWaterCoopers Report, Leadership in Affordable Therepeutic Products: A Biopharma Strategy for India available at last visited on 22nd Februaury 2013.

Available at

(BioSpectrum-ABLE top 20 survey 2012)

Nayantara Som, India on biologics trail, http://www.biospectrumindia.commakesections.asp/1202131.asp

N Sahoo, P Manchikanti, Recombinant Drug Development, Regulation, and Commercialization: An Indian Industry Perspective, BioDrugs, 2011

J.S. Bain, Industrial Organisation, Wiley, N. Y., 1959; Christian Lennartz, Marietta Haffner and Michael Oxley, Competition between social and market renting: a theoretical application of the structure-conductperformance paradigm, J Hous and the Built Environ (2012) 27:453–471; Bain JS (1951) Relation of profit rate to industry concentration: American Manufacturing, 1936–1940. Q J Econ 65:293–324

Scherer and Ross 1990, ndustrial market structure and economic performance, Houghton Mifflin (Boston).

See G. J. Stigler, A Theory of Oligopoly, Journal of Political Economy, 72 (1964), pp. 44-61 p. 252-281.

M. A. J. Farrell, The Measurement of Productive Efficiency, J. R. S. S., 120 (1957), Series A.

Mashelkar Committee Report on Recombinant Sector.

WHO essential medicine price list, available on last accessed on 26th February 2013.

WHO Model Lists of Essential, The current versions are the 17th WHO Essential Medicines List and the 3rd WHO Essential Medicines List for Children updated in March 2011, Medicines

ABLE Report 2011.

US Department of Justice merger enforcement, available on last visited on 11th February 2013.

William M Landes and Richard A. Posner (1981), Market Power in Antitrust Cases, Harvard Law Review, 94(5), March 937-96.

Lerner J. (1934), The Concept of Monopoly and the Measurement of Monopoly Power, The Review of Economic Studies, Vol. 1, No. 3, pp. 157-175

Emerging Healthcare Issues: Follow on Biologic Drug Competition, FTC Report June 2009, available at

Video of the Subcommittee on Health held a hearing on a new Federal Trade Commission (FTC) report titled, "Emerging Health Care Issues: Follow-on Biologic Drug Competition" June 11, 2009. The report states FTC findings with respect to its investigation into the effects of a follow-on biologics pathway on competition and innovation. In particular, the report discusses whether additional incentives in addition to patents and pricing, are needed to ensure continued innovation in the biologics market.

available on

Biologics, Biosimilar Market Overview, AvesthgenBringing Science to Life Report.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.